West Nile Virus detected in Essex County, health unit says
Routine monitoring has identified positive mosquito pools in the community, the health unit said in a news release issued Monday.
But it has not identified any cases in humans yet.
"Windsor and Essex County residents should continue to protect themselves against mosquitoes," said Dr. Mehdi Aloosh, medical officer of health for Windsor-Essex.
"This is an important reminder for everyone to remove standing water around our homes and workplaces to prevent mosquito breeding and protect ourselves and our families from mosquito bites."
West Nile virus is transmitted to humans through bites from infected mosquitoes.
Seventy to 80 per cent of those infected will have no symptoms, and others will have mild symptoms such as fever, headache, body aches, a mild rash and swollen lymph glands, according to Health Canada.
Small percentage of cases can cause serious illness
But a small number of people – fewer than one per cent – can have serious symptoms, including a severe headache that comes on quickly, a high fever, stiff neck, nausea or vomiting, difficulty swallowing, drowsiness, confusion, loss of consciousness, lack of coordination, muscle weakness or paralysis.
Some severe cases can be fatal.
First symptoms usually appear within two to 15 days after infection, Health Canada said.
Adults over 49 and those with underlying conditions or weaker immune systems are at greater risk of more severe illness.
The health unit has issued the following tips to help people protect themselves from mosquito bites.
Use insect repellents that contain DEET, Icaridin or other approved ingredients on clothing and exposed skin. Always read and follow label directions.
Wear long-sleeved shirts, long pants and a hat when outdoors. Light-coloured clothing is best, as mosquitoes tend to be attracted to dark colours.
Limit the time you spend outdoors at dawn and dusk, when mosquitoes are most active.
Remove any standing water in places such as bird baths, buckets, old tires, pet water dishes and gutters around property.
Make sure that door and window screens fit securely and are free of holes.
Call 311 or local by-law enforcement about standing water observed in the community.
The health unit and municipal governments will continue to monitor for the virus, the health unit said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
8 minutes ago
- National Post
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
Article content Reported positive Phase 1b data in five adults with Duchenne muscular dystrophy (DMD) after 28 days of treatment Demonstrated safety, tolerability and an approximate doubling in grip strength On track to initiate a follow-up of the Phase 1b study in adults with DMD in Q3 2025 Expected to report 3-month interim data this year Preparing submissions to enable initiation of a global Phase 2 randomized, placebo-controlled clinical trial in children with DMD Appointed Dr. Wildon Farwell as chief medical officer (CMO) Ended the second quarter of 2025 with cash balance of $52.1 million ($38.2 million in $U.S.) Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced its financial results and corporate highlights for the second quarter ended June 30, 2025. Article content 'We are excited by the clean safety profile and promising functional improvements with SAT-3247 in our Phase 1a/1b study,' said Satellos Co-Founder and Chief Executive Officer Frank Gleeson. 'The consistency between our clinical and preclinical findings continues to point to the transformative potential of SAT-3247 as a novel treatment for degenerative muscle conditions broadly. In Duchenne, current therapies are making important progress in slowing disease progression and preserving muscle. We designed SAT-3247 to do something different — help rebuild muscle and improve strength. We look forward to our imminent Phase 1b long-term follow-up trial in adults and planned Phase 2 study with children, where we aim to demonstrate how SAT-3247 may contribute to that most important goal of improving functional outcomes for people living with Duchenne through a potentially safe, disease modifying, oral treatment.' Article content On May 22, 2025, Satellos announced positive Phase 1b results from a 28-day open-label study in five adult male patients with DMD (ages 20–27). SAT-3247 was safe and well tolerated in all participants Grip strength, measured using the standardized MyoGrip device, showed an approximate doubling across the 5 participants from ~ 2 kg to 4 kg. In addition, patients demonstrated an approximate average increase in force-vital capacity of 5%. Study participants appeared to remain stable in other exploratory measurement areas. The expected pharmacokinetic of SAT-3247 was met — an important result with these patients who were all on steroids. Building on these positive outcomes, Satellos received approval and plans to initiate SAT-3247-LT-001 in Q3 2025. This will offer an additional 11 months of treatment for adult participants from the initial 28-day Phase 1b trial. The study will assess the durability of functional responses, longer-term safety, and changes in muscle composition as measured by MRI. Interim 3-month results are expected prior to year-end. Satellos also plans to expand the protocol to include additional patients. Global Phase 2 trial for pediatric patients with DMD: Satellos is on track to submit an IND application to the FDA and CTAs in other countries in Q3 2025 to enable initiation — subject to regulatory approval — of a global Phase 2 randomized, placebo-controlled, proof-of-concept trial in pediatric patients with DMD. The planned trial is designed to assess safety, pediatric pharmacokinetics, optimal dose, biologic effects, and measures of functional efficacy. Article content FINANCIAL RESULTS (in $U.S.) Article content Satellos had cash and cash equivalents and short-term investments of $38.2 million as of June 30, 2025, compared with $48.5 million at Dec. 31, 2024. The decrease in funds available is due to the net loss in the current year period, as well as increased deposits related to the planned Phase 2 clinical trial. Article content For the three-months ended June 30, 2025, Satellos reported a net loss of $5.6 million ($0.03 loss per share), compared to a net loss of $4.4 million ($0.04 loss per share) for the three-months ended June 30, 2024. The increase in net loss for the three-months ended June 30, 2025, compared with the same period in 2024, was a result of increased research and development (R&D) expenses, as well as increased general and administrative (G&A) expenses. Article content R&D expenses increased to $4.4 million for the three-months ended June 30, 2025, compared to $3.6 million for the three-months ended June 30, 2024. The increase in R&D expenses was the result of increased clinical costs associated with ongoing and planned clinical trials, partially offset by decreased CMC activities related to the process development and manufacturing of SAT-3247 for clinical use in the prior year period and preclinical costs due to IND enabling studies conducted to support the clinical regulatory filings for SAT-3247 as we prepared to initiate Phase 1 clinical development in Q3 2024. Article content G&A expenses increased to $1.9 million for the three-months ended June 30, 2025, as compared to $1.3 million for the three-months ended June 30, 2024. The increase in general and administrative expenses in the current year period is primarily the result of increased salary and professional fees related to changes in headcount to support expanded operations and non-cash stock-based compensation expense due to new grants issued in the current period. Article content The Satellos consolidated interim financial statements for the three- and six-months ended June 30, 2025, and the related management discussion and analysis will be available on SEDAR+ at Article content ABOUT SAT-3247 Article content SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne muscular dystrophy and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status. Article content ABOUT SATELLOS BIOSCIENCE INC. Article content Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, expected timing for Phase 2 regulatory filings, the timing of initiating the Phase 1b long term follow up study and when three month interim data will be available, estimated runway based on cash on hand; statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. Article content Article content Article content Article content Article content Contacts Article content Investors: Article content Liz Williams, CFO, Article content ir@ Article content Article content Media: Article content Emily Williams, Senior Director of Communications, Article content Article content
Globe and Mail
38 minutes ago
- Globe and Mail
Happy Belly Food Group's Heal Wellness Secures Real-Estate Location in Downtown Oakville, Ontario
Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) (" Happy Belly" or the " Company"), a leader in acquiring and scaling emerging food brands across Canada is pleased to announce that its Heal Wellness brand has secured a real estate location in downtown Oakville, Ontario, with plans to open the 8 th corporate store for the brand. Heal Wellness (" Heal") is a fresh smoothie bowls, acai bowls, and smoothies quick serve restaurant ("QSR"). To view an enhanced version of this graphic, please visit: "Securing our next corporate store location is an example of Happy Belly exercising its disciplined organic growth model, using free cash flow from our brand to compound growth. With a focus on (ROIC) Return on Invested Capital we believe this was the right time and location to accelerate our corporate store count. Capital allocation across our brand portfolio is critical as we look to accelerate our growth and maximize returns for our shareholders", said Sean Black, Chief Executive Officer of Happy Belly Food Group. We believe having a disciplined approach to growth by using both our corporate and franchised locations will establish Heal Wellness as the leading smoothie bowl brand in Canada." "Heal is building strong momentum, expanding its development pipeline with a consistent flow of franchise agreements and strategic real estate acquisitions nationwide. Striking the right balance between corporate and franchised locations remains a key metric as we grow our national footprint. Rapidly positioning itself as Canada's first genuine coast-to-coast smoothie bowl brand, Heal is gaining significant traction in emerging markets while cultivating loyal customers and enhancing brand awareness—reinforcing our long-term vision and the strength of our brand model." "We believe downtown Oakville, with its vibrant, health-conscious community and strong foot traffic from both residents and visitors will make this location a perfect fit for Heal. The surrounding area boasts a mix of upscale shops, cafes, and fitness studios that attract a demographic focused on wellness and nutritious lifestyle choices, perfectly aligning with the fresh and wholesome offerings of Heal's acai bowls and smoothies. Additionally, its picturesque lakeside setting and active outdoor culture encourage healthy eating habits, making it a natural fit for a health-focused quick-service restaurant. With excellent accessibility and a growing demand for convenient, nutritious options, downtown Oakville presents a prime opportunity for Heal to grow its customer base." To view an enhanced version of this graphic, please visit: "Heal Wellness is rapidly gaining national brand recognition, establishing itself as Canada's first true coast-to-coast smoothie bowl brand as it gains traction across new markets, building customer loyalty and brand visibility at an impressive pace—further validating our long-term vision and the strength of our franchise model. With 195 units secured through national development agreements—Heal is delivering on its promise of scalable, asset-light expansion while deepening customer loyalty and market presence. Our progress reinforces our expansion strategy while generating long-term value creation for our shareholders." "The broader Happy Belly portfolio now boasts 616 contractually committed retail locations across various stages of development, construction, and operation. This momentum—fueled by a proven franchise model, experienced operators, and strategic site selection—is translating into meaningful and shareholder value. As we scale nationally with a repeatable, asset-light framework, we are laying the foundation for sustained and predictable growth across our entire brand ecosystem through 2026 and beyond." "We are just getting started," said Sean Black. About Heal Wellness Heal Wellness was founded with a passion and mission to provide quick, fresh wellness foods that support a busy and active lifestyle. We currently offer a diverse range of smoothie bowls and smoothies. We take pride in meticulously selecting every superfood ingredient on our menu to fuel the body, including acai smoothie bowls, smoothies, and super-seed grain bowls. Our smoothie bowls are crafted with real fruit and enriched with superfoods like acai, pitaya, goji berries, chia seeds, and more. Franchising For franchising inquiries please see or contact us at hello@ Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company") is a leader in acquiring and scaling emerging food brands across Canada. Happy Belly 3 To view an enhanced version of this graphic, please visit: Sean Black Co-Founder, Chief Executive Officer Shawn Moniz Co-Founder, Chief Operating Officer Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management. Cautionary Note Regarding Forward-Looking Statements All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. Forward-Looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include the future performance of Happy Belly and her subsidiaries. Forward-Looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the business plans for Happy Belly described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on
CTV News
39 minutes ago
- CTV News
Swimming advisories issued for Orillia beaches
Four youths cool down during some extreme heat Monday afternoon, June 23, 2025. (Rick Barbero/The Register-Herald via AP) Two of Orillia's busiest beach parks have been flagged with a high bacteria count in the water. To that end, the Simcoe Muskoka District Health Unit has issued swimming advisories for Couchiching Beach at Couchiching Beach Park, and Moose Beach located at J.B. Tudhope Memorial Park. Swimming advisories are issued when the bacteria levels exceed those considered safe by the health unit. An advisory is a warning to swimmers, but not a beach closure. The two beaches are posted with warning signs indicating there may be an increased risk of developing minor irritations and infections. If people choose to swim during a swimming advisory, it may be prudent to avoid ducking their head underwater or swallowing the water. Additionally, lifeguards are off duty during a swim advisory, and swimmers are cautioned to swim at their own risk. Bacteria counts are affected many different factors with the most common being rain, wind and waterfowl. A reminder that due to the heat, cooling centres are open to the public at the Orillia Public Library and Orillia Recreation Centre. Splash pads are also available throughout the city.
